NOTCH1 and B-cell chronic lymphocytic leukemia: In a real-life study on the efficacy of ibrutinib as a single agent in 180 patients with CLL recruited from three independent cohorts from Italy, 73 patients were reported to have discontinued ibrutinib for progression or for AEs, while NOTCH1-mutated patients were reported to have less redistribution lymphocytosis at 3 months on ibrutinib, to show inferior nodal response at 6 months, and to have significantly shorter PFS and OS [28].